John Stephen West Net Worth

The estimated Net Worth of John Stephen West is at least $15.5 Milhão dollars as of 14 December 2022. Mr West owns over 10,000 units of Personalis Inc stock worth over $3,703,542 and over the last 5 years he sold PSNL stock worth over $10,763,572. In addition, he makes $1,033,500 as Co-Founder, CEO, e Pres & Director at Personalis Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr West PSNL stock SEC Form 4 insiders trading

Mr has made over 12 trades of the Personalis Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of PSNL stock worth $24,400 on 14 December 2022.

The largest trade he's ever made was selling 110,000 units of Personalis Inc stock on 8 July 2021 worth over $2,479,400. On average, Mr trades about 31,010 units every 23 days since 2019. As of 14 December 2022 he still owns at least 622,444 units of Personalis Inc stock.

You can see the complete history of Mr West stock trades at the bottom of the page.

Mr. John Stephen West biography

John Stephen West is the Co-Founder, CEO, Pres & Director at Personalis Inc.

What is the salary of Mr West?

As the Co-Founder, CEO, e Pres & Director of Personalis Inc, the total compensation of Mr West at Personalis Inc is $1,033,500. There are 2 executives at Personalis Inc getting paid more, with Aaron Tachibana having the highest compensation of $3,003,510.

How old is Mr West?

Mr West is 64, he's been the Co-Founder, CEO, e Pres & Director of Personalis Inc since . There are 4 older and 12 younger executives at Personalis Inc. The oldest executive at Personalis Inc is A. Blaine Bowman, 73, who is the Independent Director.

What's Mr West's mailing address?

John's mailing address filed with the SEC is C/O PERSONALIS, INC., 6600 DUMBARTON CIRCLE, FREMONT, CA, 94555.

Insiders trading at Personalis Inc

Over the last 5 years, insiders at Personalis Inc have traded over $56,423,548 worth of Personalis Inc stock and bought 5,708,990 units worth $54,066,334 . The most active insiders traders include Llp Abingworth, Paul Ricci, eAi, Inc. Tempus. On average, Personalis Inc executives and independent directors trade stock every 15 days with the average trade being worth of $410,996. The most recent stock trade was executed by Ai, Inc. Tempus on 16 August 2024, trading 3,500,000 units of PSNL stock currently worth $17,745,000.

What does Personalis Inc do?

personalis is a genome-scale diagnostics company with a mission to pioneer genome guided medicine. our priority is to obtain the most accurate genetic data from each sample, and then to draw the most reliable medically-focused conclusions from these. our tests are based on whole human genome and exome sequencing, conducted in our state-of-the art laboratory. we analyze results utilizing proprietary databases, advanced human reference sequences, and sophisticated algorithms. personalis genome services provides academic, pharmaceutical, and biotech researchers an accurate and comprehensive end-to-end human genome sequencing and analysis solution. our services support researchers engaging in large case-control and family-based genome studies of complex or mendelian diseases and traits, pharmacogenomics, and cancer.

Complete history of Mr West stock trades at Personalis Inc

Personalis Inc executives and stock owners

Personalis Inc executives and other stock owners filed with the SEC include:

• Aaron Tachibana,
  Chief Financial Officer
• Clinton Musil,
  Chief Business Officer
• John Stephen West,
  Co-Founder, CEO, Pres & Director
• Paul Ricci,
  Independent Director
• John West,
  President, Chief Executive Officer, Director
• Dr. Richard Chen M.D., M.S., MS,
  Sr. VP of R&D and Chief Medical Officer
• Richard Chen,
  Chief Science Officer
• Aaron L. Tachibana,
  Sr. VP & CFO
• Dr. Richard Chen M.S., M.D., MS,
  Chief Scientific Officer
• A. Blaine Bowman,
  Independent Director
• Alan Colowick,
  Independent Director
• Karin Eastham,
  Independent Director
• Jonathan MacQuitty,
  Independent Chairman of the Board
• Kenneth Ludlum,
  Independent Director
• Patrick Balthrop,
  Independent Director
• Stephen Moore,
  General Counsel
• Dr. Euan A. Ashley DPHIL, FRCP, M.D., Ph.D.,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Prof. Russ B. Altman M.D., Ph.D.,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Michael J. Fitzpatrick,
  VP of Worldwide Sales
• Stephen M. Moore J.D.,
  VP, Gen. Counsel & Corp. Sec.
• Carol J. Tillis,
  VP of Fin. & Admin.
• Dr. Michael Snyder Ph.D.,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Dr. Atul Butte,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Dr. Euan A. Ashley M.D., Ph.D., FRCP, DPHIL,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Prof. Russ B. Altman,
  Co-Founder and Member of Clinical & Scientific Advisory Board
• Kenneth J Widder,
  
• Olivia Kyusuk Bloom,
  
• Ken Ludlum,
  Director
• Mdv Partners, L.L.C.Mdv Ix ...,
  
• Venture Partners Viii Lp Li...,
  
• Venture Partners Select Iv,...,
  
• Llp Abingworth,
  
• Christopher M Hall,
  PRESIDENT AND CEO
• Venture Partners Select Iv,...,
  
• Ai, Inc. Tempus,
  10% owner
• Lonnie Shoff,